Paper23242597
The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome.
Costantini B and 9 others. Haematologica, 2013. Cited by 96 papers, by iCite.
Cite this record
ConductScience Library. The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. Papers, record 23242597. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23242597
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Azacitidine | Major topic |
| Myelodysplastic Syndromes | Major topic |
| T-Lymphocytes, Regulatory | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Lymphocyte Count | |
| Male | |
| Middle Aged | |
| Th1 Cells | |
| Th17 Cells | |
| Th2 Cells | |
| Treatment Outcome |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| MR/J006742/1 | Medical Research Council | United Kingdom | PubMed |
Source PubMed
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17611569 | CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. | Leukemia | 2007 | https://conductscience.org/library/papers/17611569 | PubMed |
| 2 | 8943243 | The proximal regulatory element of the interferon-gamma promoter mediates selective expression in T cells. | J Biol Chem | 1996 | https://conductscience.org/library/papers/8943243 | PubMed |
| 3 | 21098230 | IL-17- and IFN-γ-secreting Foxp3+ T cells infiltrate the target tissue in experimental autoimmunity. | J Immunol | 2010 | https://conductscience.org/library/papers/21098230 | PubMed |
| 4 | 19151746 | Epigenetic control of T-helper-cell differentiation. | Nat Rev Immunol | 2009 | https://conductscience.org/library/papers/19151746 | PubMed |
| 5 | 8551029 | Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. | J Immunol Methods | 1995 | https://conductscience.org/library/papers/8551029 | PubMed |
| 6 | 19887673 | Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. | Blood | 2010 | https://conductscience.org/library/papers/19887673 | PubMed |
| 7 | 19230772 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19230772 | PubMed |
| 8 | 18566595 | How regulatory T cells work. | Nat Rev Immunol | 2008 | https://conductscience.org/library/papers/18566595 | PubMed |
| 9 | 17412885 | CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). | Blood | 2007 | https://conductscience.org/library/papers/17412885 | PubMed |
| 10 | 7527544 | Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. | Proc Natl Acad Sci U S A | 1994 | https://conductscience.org/library/papers/7527544 | PubMed |
| 11 | 16707479 | DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. | Cancer Res | 2006 | https://conductscience.org/library/papers/16707479 | PubMed |
| 12 | 16952911 | Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets. | Carcinogenesis | 2006 | https://conductscience.org/library/papers/16952911 | PubMed |
| 13 | 19389880 | A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. | Blood | 2009 | https://conductscience.org/library/papers/19389880 | PubMed |
| 14 | 17591856 | CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. | J Exp Med | 2007 | https://conductscience.org/library/papers/17591856 | PubMed |
| 15 | 22555974 | Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. | Blood | 2012 | https://conductscience.org/library/papers/22555974 | PubMed |
| 16 | 21493801 | Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. | Blood | 2011 | https://conductscience.org/library/papers/21493801 | PubMed |
| 17 | 18206726 | Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. | Exp Hematol | 2008 | https://conductscience.org/library/papers/18206726 | PubMed |
| 18 | 12495905 | DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. | Haematologica | 2002 | https://conductscience.org/library/papers/12495905 | PubMed |
| 19 | 21435589 | CD4(+)CD25(+)Foxp3(+) regulatory T cells promote Th17 cells in vitro and enhance host resistance in mouse Candida albicans Th17 cell infection model. | Immunity | 2011 | https://conductscience.org/library/papers/21435589 | PubMed |
| 20 | 17998812 | Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. | Epigenetics | 2006 | https://conductscience.org/library/papers/17998812 | PubMed |
Cited by71
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 96 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42558501 | Hypomethylating agents are the current therapy backbone for MDS and AML relapsing after allogeneic hematopoietic stem cell transplantation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42558501 | PubMed |
| 42367853 | Azacytidine restores T cell function in AML by modulating DNA methylation. | bioRxiv | 2026 | https://conductscience.org/library/papers/42367853 | PubMed |
| 42279389 | Myeloid Malignancies Beyond the Cell: Targeting the Tumour Microenvironment with Next-Generation Immunotherapies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42279389 | PubMed |
| 41531276 | Hypomethylating agents in vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review. | Br J Haematol | 2026 | https://conductscience.org/library/papers/41531276 | PubMed |
| 40675972 | Humanized mouse models in MDS. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/40675972 | PubMed |
| 40473616 | A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence. | Nat Commun | 2025 | https://conductscience.org/library/papers/40473616 | PubMed |
| 40038722 | The epigenetic hallmarks of immune cells in cancer. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40038722 | PubMed |
| 39949137 | [Pathogenesis and treatment progression of myelodysplastic syndrome combined with Behçet's syndrome]. | Zhejiang Da Xue Xue Bao Yi Xue Ban | 2025 | https://conductscience.org/library/papers/39949137 | PubMed |
| 39594638 | Understanding Myelodysplasia and Inflammation Through the Lense of VEXAS Syndrome: A Review. | Cells | 2024 | https://conductscience.org/library/papers/39594638 | PubMed |
| 39485042 | Single-Cell Analysis of Bone Marrow CD8+ T Cells in Myeloid Neoplasms Reveals Pathways Associated with Disease Progression and Response to Treatment with Azacitidine. | Cancer Res Commun | 2024 | https://conductscience.org/library/papers/39485042 | PubMed |
| 39376992 | Molecular profiling of pre- and post- 5-azacytidine myelodysplastic syndrome samples identifies predictors of response. | Front Oncol | 2024 | https://conductscience.org/library/papers/39376992 | PubMed |
| 39287751 | Clinical efficacy and immune response of BCL-2 inhibitors combined with hypomethylating agents in the treatment of acute myeloid leukemia. | Discov Oncol | 2024 | https://conductscience.org/library/papers/39287751 | PubMed |
| 39030997 | Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. | Cancer Med | 2024 | https://conductscience.org/library/papers/39030997 | PubMed |
| 38917523 | The DNA methylation landscape across the TCR loci in patients with acute myeloid leukemia. | Int Immunopharmacol | 2024 | https://conductscience.org/library/papers/38917523 | PubMed |
| 38840907 | Case report: VEXAS syndrome: an atypical indolent presentation as sacroiliitis with molecular response to azacitidine. | Front Immunol | 2024 | https://conductscience.org/library/papers/38840907 | PubMed |
| 38044445 | Targeting the epigenome to reinvigorate T cells for cancer immunotherapy. | Mil Med Res | 2023 | https://conductscience.org/library/papers/38044445 | PubMed |
| 38003240 | HCV and HCC Tango-Deciphering the Intricate Dance of Disease: A Review Article. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38003240 | PubMed |
| 37809078 | Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy. | Front Immunol | 2023 | https://conductscience.org/library/papers/37809078 | PubMed |
| 37501758 | VEXAS Syndrome-Review. | Glob Med Genet | 2023 | https://conductscience.org/library/papers/37501758 | PubMed |
| 37217462 | Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/37217462 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| FOXP3 | 50943 | PubTator's text mining | https://conductscience.org/library/genes/50943 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23242597
GET https://conductscience.org/api/papers/v1/23242597/references?page=2